传单修改技术,以减轻冠状动脉阻塞的风险,在横导管大动脉植入过程中
Sunny Goel1,2, Richard Tanner1,3, Kwong-Yue Eric Chan4
1Division of Cardiology, The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
概括
通过导管的大动脉植入 (TAVI) 可以导致冠状动脉阻塞. 传单修改技术如BASILICA,ShortCut和UNICORN旨在防止这种严重的并发症,改善患者的治疗结果.
科学领域:
- 心血管干预 心血管干预
- 结构性心脏病是什么
- 医疗器械技术 医疗器械技术
背景情况:
- 冠状动脉阻塞是一种罕见但危及生命的并发症,发生在跨导管大动脉植入 (TAVI) 过程中,特别是在门内程序中.
- 与冠状动脉阻塞相关的高死亡率需要预防策略.
研究的目的:
- 审查和比较各种传单修改技术,以防止TAVI期间冠状动脉阻塞.
- 评估不同方法的有效性,挑战和结果,在原生和门内 TAVI 设置中.
主要方法:
- 关于TAVI的传单修改技术的现有文献的审查.
- 详细讨论生物假体或本地大动脉贝故意撕裂,以防止阳性冠状动脉阻塞 (BASILICA),短路切断和用射频针破坏阳性冠状动脉阻塞 (UNICORN).
- 分析程序复杂性,设备需求和临床结果.
主要成果:
- 贝西利卡,短路切割和独角兽是预防阳性冠状动脉阻塞的关键技术.
- 这些方法的复杂性,所需的设备和所取得的临床结果各不相同.
- 对每种技术的有效性,潜在的并发症和程序性挑战进行了讨论.
结论:
- 传单修改技术对于减轻TAVI冠状动脉阻塞风险至关重要.
- 仔细的患者选择和先进的成像对于成功实施至关重要.
- 需要进一步的研究来优化这些策略,以提高TAVI的安全性.
相关概念视频
Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...


